与肺腺癌中的EGFR突变状态相关的HIF-1α/PKM2反循环
Yuan Wang1, Hongguang Lian1, Jiajun Li2
1Department of Pathology, The Second Hospital, Hebei Medical University, Shijiazhuang, China.
肺腺癌 (LUAD) 中表皮生长因子受体 (EGFR) 突变与更高水平的代谢调节剂HIF-1α和PKM2有关. 这表明EGFR状态与促进癌症生长的HIF-1α/PKM2反循环之间存在联系.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 基因突变驱动独特的代谢表型,这对于癌细胞增殖至关重要.
- 皮表皮生长因子受体 (EGFR) 突变是肺腺癌 (LUAD) 的主要致癌驱动因素.
- 低氧诱导因子1-α (HIF-1α) 和酸盐激酶M2 (PKM2) 形成一个反循环,促进糖解和癌症生长.
研究的目的:
- 评估EGFR突变状态与LUAD中的HIF-1α/PKM2反循环之间的关系.
- 研究LUAD中HIF-1α和PKM2的差异表达和临床意义.
- 探索EGFR突变与代谢调节蛋白HIF-1α和PKM2.2之间的相关性.
主要方法:
- 对89名接受手术切除的LUAD患者进行了回顾性研究.
- 使用实时PCR进行EGFR突变分析.
- 免疫组织化学测量HIF-1α和PKM2蛋白质的表达.
主要成果:
- 与正常肺组织相比,LUAD中的HIF-1α和PKM2蛋白表达显著增加.
- 较高的HIF-1α和PKM2表达与LUAD中先进的pTNM阶段相关.
- 与EGFR野生型瘤相比,EGFR突变 (EGFR-mt) LUAD瘤的HIF-1α和PKM2水平更高.
- HIF-1α和PKM2表达显示出正相关性,特别是在EGFR-mt LUAD中.
- HIF-1α表达与先进的pTNM阶段相关,PKM2在EGFR突变瘤中表现出类似的趋势.
结论:
- HIF-1α/PKM2反循环在LUAD中具有差异性表达,特别是在EGFR突变瘤中.
- 这项研究支持EGFR突变状态与肺腺癌中关键的有氧糖解调节剂HIF-1α和PKM2之间存在显著的关系.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Mitogens and the Cell Cycle
Regulation of Angiogenesis and Blood Supply
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
